The Emergency Use of the oXiris Device with Continuous Kidney Replacement Therapy in COVID-19 Patients with Acute Kidney Injury

Raina, Rupesh; Mawby, Isabelle; Datla, Nikhil; Chakraborty, Ronith; Mehra, Kabir; Singh, Siddhartha; Agrawal, Nirav; Botsch, Alexander; Neyra, Javier A.

doi:10.26502/acbr.50170189

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the setting of severe COVID-19 infection, Acute Kidney Injury Network (AKIN) class III, ARDS, and fluid overload, Raina et al . [ 22 ] published a case report in which the oXiris membrane was utilized, resulting in a total resolution of kidney function. Notably, in this instance, a protocol was developed for the priming of the filter.…”

Section: Introductionmentioning

confidence: 99%

AKI in adults with COVID-19 infection: Mechanisms of development and role of blood filtration devices in treatment

Bansal,

Hu,

Raina

et al. 2023

Indian J Nephrol

View full text Add to dashboard Cite

During the coronavirus disease 2019 (COVID-19) pandemic, acute kidney injury (AKI) was a common sequela of COVID-19 infection and predicted disease severity and mortality. Extracorporeal blood purification techniques involving blood filtration devices are an emerging treatment for AKI in the setting of severe COVID-19 infections. In this review, we discuss potential mechanisms for the development of AKI in COVID-19 patients as well as the various available blood filtration devices and the role they may play in managing the AKI in COVID-19 patients. A total of seven blood filters currently available were compared based on their potential in treating AKI in COVID-19 patients. Blood filtration devices show potential as an emerging treatment modality for COVID-19–induced AKI, but further clinical trials are necessary before their widespread adoption and usage.

show abstract

Section: Introductionmentioning

confidence: 99%